| Title: | Assessing the Role of Rare Genetic Variation in Patients With Heart Failure |
| Journal: | JAMA Cardiology |
| Published: | 1 Apr 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33326012/ |
| DOI: | https://doi.org/10.1001/jamacardio.2020.6500 |
| URL: | https://jamanetwork.com/journals/jamacardiology/articlepdf/2773805/jamacardiology_povysil_2020_oi_200086_1617381086.66625.pdf |
Publication 4110
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Importance: Sequencing studies have identified causal genetic variants for distinct subtypes of heart failure (HF) such as hypertrophic or dilated cardiomyopathy. However, the role of rare, high-impact variants in HF, for which ischemic heart disease is the leading cause, has not been systematically investigated.</p>
Objective: To assess the contribution of rare variants to all-cause HF with and without reduced left ventricular ejection fraction.</p>
Design, Setting, and Participants: This was a retrospective analysis of clinical trials and a prospective epidemiological resource (UK Biobank). Whole-exome sequencing of patients with HF was conducted from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials. Data were collected from March 1999 to May 2003 for the CHARM studies and September 2003 to July 2007 for the CORONA study. Using a gene-based collapsing approach, the proportion of patients with HF and controls carrying rare and presumed deleterious variants was compared. The burden of pathogenic variants in known cardiomyopathy genes was also investigated to assess the diagnostic yield. Exome sequencing data were generated between January 2018 and October 2018, and analysis began October 2018 and ended April 2020.</p>
Main Outcomes and Measures: Odds ratios and P values for genes enriched for rare and presumed deleterious variants in either patients with HF or controls and diagnostic yield of pathogenic variants in known cardiomyopathy genes.</p>
Results: This study included 5942 patients with HF and 13 156 controls. The mean (SD) age was 68.9 (9.9) years and 4213 (70.9%) were male. A significant enrichment of protein-truncating variants in the TTN gene (P = 3.35 × 10-13; odds ratio, 2.54; 95% CI, 1.96-3.31) that was further increased after restriction to variants in exons constitutively expressed in the heart (odds ratio, 4.52; 95% CI, 3.10-6.68). Validation using UK Biobank data showed a similar enrichment (odds ratio, 4.97; 95% CI, 3.94-6.19 after restriction). In the clinical trials, 201 of 5916 patients with HF (3.4%) had a pathogenic or likely pathogenic cardiomyopathy variant implicating 21 different genes. Notably, 121 of 201 individuals (60.2%) had ischemic heart disease as the clinically identified etiology for the HF. Individuals with HF and preserved ejection fraction had only a slightly lower yield than individuals with midrange or reduced ejection fraction (20 of 767 [2.6%] vs 15 of 392 [3.8%] vs 166 of 4757 [3.5%]).</p>
Conclusions and Relevance: An increased burden of diagnostic mendelian cardiomyopathy variants in a broad group of patients with HF of mostly ischemic etiology compared with controls was observed. This work provides further evidence that mendelian genetic conditions may represent an important subset of complex late-onset diseases such as HF, irrespective of the clinical presentation.</p>
10 Keywords
- Aged
- Case-Control Studies
- Exome Sequencing
- Female
- Genetic Predisposition to Disease
- Genetic Variation
- Heart Failure
- Humans
- Male
- Retrospective Studies
12 Authors
- Gundula Povysil
- Olympe Chazara
- Keren J. Carss
- Sri V. V. Deevi
- Quanli Wang
- Javier Armisen
- Dirk S. Paul
- Christopher B. Granger
- John Kjekshus
- Vimla Aggarwal
- Carolina Haefliger
- David B. Goldstein
Enabling scientific discoveries that improve human health